Pfizer Inc. is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.
https://www.pharmalive.com/wp-content/uploads/2023/01/ReutersPaxlovid1-20-2023.jpg7721200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-01-10 00:36:252023-01-10 10:37:44Pfizer CEO rules out generic COVID drug Paxlovid for China
